Literature DB >> 31952687

Continuing challenges in targeting oligomeric GPCR-based drugs.

Joaquin Botta1, Julia Appelhans1, Peter J McCormick2.   

Abstract

This chapter will focus on the therapeutic potential of oligomeric GPCR structures. We will discuss the history of these complexes and their connection with treatment. We will highlight several examples from the literature of complexes of therapeutic or theranostic opportunity. As part of this we will discuss different mechanisms that oligomers use to modulate their partner that could be taken advantage of from a drug targeting perspective. We will also discuss the challenges and hurdles to targeting such complexes.
© 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bivalent ligands; G protein-coupled oligomers; GPCR cross-talk; GPCR homomers; Heteromers; Interference peptides

Mesh:

Substances:

Year:  2020        PMID: 31952687     DOI: 10.1016/bs.pmbts.2019.11.009

Source DB:  PubMed          Journal:  Prog Mol Biol Transl Sci        ISSN: 1877-1173            Impact factor:   3.622


  5 in total

1.  Allosteric ligands control the activation of a class C GPCR heterodimer by acting at the transmembrane interface.

Authors:  Lei Liu; Zhiran Fan; Xavier Rovira; Li Xue; Salomé Roux; Isabelle Brabet; Mingxia Xin; Jean-Philippe Pin; Philippe Rondard; Jianfeng Liu
Journal:  Elife       Date:  2021-12-06       Impact factor: 8.140

Review 2.  The Interplay of Endothelial P2Y Receptors in Cardiovascular Health: From Vascular Physiology to Pathology.

Authors:  Cendrine Cabou; Laurent O Martinez
Journal:  Int J Mol Sci       Date:  2022-05-24       Impact factor: 6.208

3.  Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.

Authors:  Bashaier Al-Zaid; Siby Chacko; Charles Ifeamalume Ezeamuzie; Moritz Bünemann; Cornelius Krasel; Tina Karimian; Peter Lanzerstorfer; Suleiman Al-Sabah
Journal:  Pharmacol Res Perspect       Date:  2022-10

Review 4.  Novel approaches and current challenges with targeting the endocannabinoid system.

Authors:  Paula Morales; Nadine Jagerovic
Journal:  Expert Opin Drug Discov       Date:  2020-04-27       Impact factor: 7.050

5.  Bivalent ligands promote endosomal trafficking of the dopamine D3 receptor-neurotensin receptor 1 heterodimer.

Authors:  Julian Budzinski; Simone Maschauer; Hiroyuki Kobayashi; Pierre Couvineau; Hannah Vogt; Peter Gmeiner; Anna Roggenhofer; Olaf Prante; Michel Bouvier; Dorothee Weikert
Journal:  Commun Biol       Date:  2021-09-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.